Which has stronger earnings and valuation, ENOV or LIVN?

LivaNova has lower revenue, but higher earnings than Enovis. Enovis is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enovis $2.25B 0.45 -$1.18B -$19.26 N/A LivaNova $1.39B 3.03 -$242.47M $3.38 22.60

Is ENOV or LIVN more profitable?

LivaNova has a net margin of 12.82% compared to Enovis' net margin of -47.96%. LivaNova's return on equity of 16.35% beat Enovis' return on equity. Company Net Margins Return on Equity Return on Assets Enovis -47.96% 12.03% 4.91% LivaNova 12.82% 16.35% 7.76%

Does the media favor ENOV or LIVN?

In the previous week, Enovis had 1 more articles in the media than LivaNova. MarketBeat recorded 9 mentions for Enovis and 8 mentions for LivaNova. LivaNova's average media sentiment score of 0.71 beat Enovis' score of -0.06 indicating that LivaNova is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enovis 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral LivaNova 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ENOV or PLSE more profitable?

Enovis has a net margin of -47.96% compared to Pulse Biosciences' net margin of -6,755.78%. Enovis' return on equity of 12.03% beat Pulse Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Enovis -47.96% 12.03% 4.91% Pulse Biosciences -6,755.78% -94.42% -79.96%

Does the media refer more to ENOV or PLSE?

In the previous week, Pulse Biosciences had 2 more articles in the media than Enovis. MarketBeat recorded 11 mentions for Pulse Biosciences and 9 mentions for Enovis. Pulse Biosciences' average media sentiment score of 0.43 beat Enovis' score of -0.06 indicating that Pulse Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enovis 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral Pulse Biosciences 2 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor IRTC or ENOV?

In the previous week, iRhythm Technologies had 6 more articles in the media than Enovis. MarketBeat recorded 15 mentions for iRhythm Technologies and 9 mentions for Enovis. iRhythm Technologies' average media sentiment score of 0.30 beat Enovis' score of -0.06 indicating that iRhythm Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iRhythm Technologies 1 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Enovis 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has higher earnings & valuation, ENOV or ATRC?

AtriCure has lower revenue, but higher earnings than Enovis. Enovis is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enovis $2.25B 0.45 -$1.18B -$19.26 N/A AtriCure $534.53M 5.31 -$11.45M $0.21 265.76

Is ENOV or ATRC more profitable?

AtriCure has a net margin of 1.85% compared to Enovis' net margin of -47.96%. Enovis' return on equity of 12.03% beat AtriCure's return on equity. Company Net Margins Return on Equity Return on Assets Enovis -47.96% 12.03% 4.91% AtriCure 1.85% 2.34% 1.77%

Does the media prefer ENOV or ATRC?

In the previous week, Enovis had 6 more articles in the media than AtriCure. MarketBeat recorded 9 mentions for Enovis and 3 mentions for AtriCure. AtriCure's average media sentiment score of 0.59 beat Enovis' score of -0.06 indicating that AtriCure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enovis 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral AtriCure 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is TMDX or ENOV more profitable?

TransMedics Group has a net margin of 22.69% compared to Enovis' net margin of -47.96%. TransMedics Group's return on equity of 15.88% beat Enovis' return on equity. Company Net Margins Return on Equity Return on Assets TransMedics Group 22.69% 15.88% 5.95% Enovis -47.96% 12.03% 4.91%

Does the media refer more to TMDX or ENOV?

In the previous week, TransMedics Group had 3 more articles in the media than Enovis. MarketBeat recorded 12 mentions for TransMedics Group and 9 mentions for Enovis. TransMedics Group's average media sentiment score of 0.53 beat Enovis' score of -0.06 indicating that TransMedics Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TransMedics Group 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enovis 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral

Enovis (ENOV) Competitors

$17.72 +0.29 (+1.66%)

Closing price 10/9/2026 03:59 PM Eastern

Extended Trading

$17.70 -0.01 (-0.08%)

As of 10/9/2026 07:30 PM Eastern

Compare

ENOV vs. LIVN, PLSE, IRTC, ATRC, and TMDX

Should you buy Enovis stock or one of its competitors? Enovis's main competitors and comparable companies include LivaNova (LIVN), Pulse Biosciences (PLSE), iRhythm Technologies (IRTC), AtriCure (ATRC), and TransMedics Group (TMDX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Enovis compare to LivaNova?

Enovis (NYSE:ENOV) and LivaNova (NASDAQ:LIVN) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment.

In the previous week, Enovis had 1 more articles in the media than LivaNova. MarketBeat recorded 9 mentions for Enovis and 8 mentions for LivaNova. LivaNova's average media sentiment score of 0.71 beat Enovis' score of -0.06 indicating that LivaNova is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enovis	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral
LivaNova	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Enovis has a beta of 1.37, meaning that its share price is 37% more volatile than the broader market. Comparatively, LivaNova has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market.

98.5% of Enovis shares are held by institutional investors. Comparatively, 97.6% of LivaNova shares are held by institutional investors. 2.9% of Enovis shares are held by insiders. Comparatively, 0.4% of LivaNova shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Enovis currently has a consensus target price of $39.50, suggesting a potential upside of 122.92%. LivaNova has a consensus target price of $87.75, suggesting a potential upside of 14.87%. Given Enovis' stronger consensus rating and higher probable upside, research analysts plainly believe Enovis is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enovis	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
LivaNova	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73

LivaNova has lower revenue, but higher earnings than Enovis. Enovis is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enovis	$2.25B	0.45	-$1.18B	-$19.26	N/A
LivaNova	$1.39B	3.03	-$242.47M	$3.38	22.60

LivaNova has a net margin of 12.82% compared to Enovis' net margin of -47.96%. LivaNova's return on equity of 16.35% beat Enovis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enovis	-47.96%	12.03%	4.91%
LivaNova	12.82%	16.35%	7.76%

Summary

LivaNova beats Enovis on 9 of the 17 factors compared between the two stocks.

How does Enovis compare to Pulse Biosciences?

Enovis (NYSE:ENOV) and Pulse Biosciences (NASDAQ:PLSE) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, media sentiment, dividends, analyst recommendations and risk.

In the previous week, Pulse Biosciences had 2 more articles in the media than Enovis. MarketBeat recorded 11 mentions for Pulse Biosciences and 9 mentions for Enovis. Pulse Biosciences' average media sentiment score of 0.43 beat Enovis' score of -0.06 indicating that Pulse Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enovis	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral
Pulse Biosciences	2 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

98.5% of Enovis shares are held by institutional investors. Comparatively, 77.0% of Pulse Biosciences shares are held by institutional investors. 2.9% of Enovis shares are held by company insiders. Comparatively, 74.0% of Pulse Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Enovis currently has a consensus target price of $39.50, indicating a potential upside of 122.92%. Pulse Biosciences has a consensus target price of $53.20, indicating a potential downside of 1.13%. Given Enovis' higher probable upside, equities research analysts clearly believe Enovis is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enovis	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Enovis has a net margin of -47.96% compared to Pulse Biosciences' net margin of -6,755.78%. Enovis' return on equity of 12.03% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enovis	-47.96%	12.03%	4.91%
Pulse Biosciences	-6,755.78%	-94.42%	-79.96%

Pulse Biosciences has lower revenue, but higher earnings than Enovis. Pulse Biosciences is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enovis	$2.25B	0.45	-$1.18B	-$19.26	N/A
Pulse Biosciences	$350K	10,884.99	-$72.78M	-$1.18	N/A

Enovis has a beta of 1.37, suggesting that its share price is 37% more volatile than the broader market. Comparatively, Pulse Biosciences has a beta of 1.57, suggesting that its share price is 57% more volatile than the broader market.

Summary

Pulse Biosciences beats Enovis on 9 of the 17 factors compared between the two stocks.

How does Enovis compare to iRhythm Technologies?

iRhythm Technologies (NASDAQ:IRTC) and Enovis (NYSE:ENOV) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, earnings, institutional ownership and profitability.

iRhythm Technologies has a beta of 1.45, indicating that its share price is 45% more volatile than the broader market. Comparatively, Enovis has a beta of 1.37, indicating that its share price is 37% more volatile than the broader market.

iRhythm Technologies currently has a consensus target price of $178.79, indicating a potential upside of 67.56%. Enovis has a consensus target price of $39.50, indicating a potential upside of 122.92%. Given Enovis' higher probable upside, analysts plainly believe Enovis is more favorable than iRhythm Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.94
Enovis	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, iRhythm Technologies had 6 more articles in the media than Enovis. MarketBeat recorded 15 mentions for iRhythm Technologies and 9 mentions for Enovis. iRhythm Technologies' average media sentiment score of 0.30 beat Enovis' score of -0.06 indicating that iRhythm Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRhythm Technologies	1 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Enovis	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

iRhythm Technologies has higher earnings, but lower revenue than Enovis. iRhythm Technologies is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRhythm Technologies	$747.14M	4.71	-$44.55M	-$0.43	N/A
Enovis	$2.25B	0.45	-$1.18B	-$19.26	N/A

98.5% of Enovis shares are held by institutional investors. 1.0% of iRhythm Technologies shares are held by company insiders. Comparatively, 2.9% of Enovis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

iRhythm Technologies has a net margin of -1.69% compared to Enovis' net margin of -47.96%. Enovis' return on equity of 12.03% beat iRhythm Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRhythm Technologies	-1.69%	10.11%	1.53%
Enovis	-47.96%	12.03%	4.91%

Summary

iRhythm Technologies beats Enovis on 10 of the 17 factors compared between the two stocks.

How does Enovis compare to AtriCure?

Enovis (NYSE:ENOV) and AtriCure (NASDAQ:ATRC) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends and valuation.

In the previous week, Enovis had 6 more articles in the media than AtriCure. MarketBeat recorded 9 mentions for Enovis and 3 mentions for AtriCure. AtriCure's average media sentiment score of 0.59 beat Enovis' score of -0.06 indicating that AtriCure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enovis	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral
AtriCure	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Enovis has a beta of 1.37, suggesting that its stock price is 37% more volatile than the broader market. Comparatively, AtriCure has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market.

98.5% of Enovis shares are held by institutional investors. Comparatively, 99.1% of AtriCure shares are held by institutional investors. 2.9% of Enovis shares are held by company insiders. Comparatively, 4.0% of AtriCure shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

AtriCure has lower revenue, but higher earnings than Enovis. Enovis is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enovis	$2.25B	0.45	-$1.18B	-$19.26	N/A
AtriCure	$534.53M	5.31	-$11.45M	$0.21	265.76

AtriCure has a net margin of 1.85% compared to Enovis' net margin of -47.96%. Enovis' return on equity of 12.03% beat AtriCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enovis	-47.96%	12.03%	4.91%
AtriCure	1.85%	2.34%	1.77%

Enovis currently has a consensus target price of $39.50, indicating a potential upside of 122.92%. AtriCure has a consensus target price of $53.30, indicating a potential downside of 4.50%. Given Enovis' stronger consensus rating and higher possible upside, analysts plainly believe Enovis is more favorable than AtriCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enovis	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
AtriCure	0 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.58

Summary

Enovis and AtriCure tied by winning 8 of the 16 factors compared between the two stocks.

How does Enovis compare to TransMedics Group?

TransMedics Group (NASDAQ:TMDX) and Enovis (NYSE:ENOV) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

99.7% of TransMedics Group shares are owned by institutional investors. Comparatively, 98.5% of Enovis shares are owned by institutional investors. 6.9% of TransMedics Group shares are owned by insiders. Comparatively, 2.9% of Enovis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

TransMedics Group has a net margin of 22.69% compared to Enovis' net margin of -47.96%. TransMedics Group's return on equity of 15.88% beat Enovis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransMedics Group	22.69%	15.88%	5.95%
Enovis	-47.96%	12.03%	4.91%

TransMedics Group currently has a consensus target price of $121.00, suggesting a potential upside of 55.39%. Enovis has a consensus target price of $39.50, suggesting a potential upside of 122.92%. Given Enovis' stronger consensus rating and higher possible upside, analysts clearly believe Enovis is more favorable than TransMedics Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransMedics Group	1 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.38
Enovis	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

TransMedics Group has a beta of 1.94, indicating that its stock price is 94% more volatile than the broader market. Comparatively, Enovis has a beta of 1.37, indicating that its stock price is 37% more volatile than the broader market.

TransMedics Group has higher earnings, but lower revenue than Enovis. Enovis is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransMedics Group	$605.49M	4.44	$190.29M	$3.89	20.02
Enovis	$2.25B	0.45	-$1.18B	-$19.26	N/A

In the previous week, TransMedics Group had 3 more articles in the media than Enovis. MarketBeat recorded 12 mentions for TransMedics Group and 9 mentions for Enovis. TransMedics Group's average media sentiment score of 0.53 beat Enovis' score of -0.06 indicating that TransMedics Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TransMedics Group	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Enovis	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

TransMedics Group beats Enovis on 12 of the 16 factors compared between the two stocks.

Get Enovis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENOV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENOV vs. The Competition

Export

Metric	Enovis	Healthcare Equipment & Supplies Industry	Healthcare Sector	NYSE Exchange
Market Cap	$1.02B	$5.49B	$7.25B	$23.07B
Dividend Yield	N/A	1.76%	2.52%	3.72%
P/E Ratio	-0.92	25.57	275.29	28.58
Price / Sales	0.45	42.88	576.46	20.68
Price / Cash	0.66	32.11	76.96	38.93
Price / Book	0.68	5.95	11.22	4.72
Net Income	-$1.18B	$146.18M	$3.50B	$1.07B
7 Day Performance	-0.02%	-0.28%	-0.89%	0.35%
1 Month Performance	-9.34%	-2.08%	-4.02%	-3.40%
1 Year Performance	-40.32%	5.39%	7.13%	9.40%

Enovis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENOV Enovis	3.37 of 5 stars	$17.72 +1.7%	$39.50 +122.9%	-40.3%	$1.02B	$2.25B	N/A	7,802	News Coverage Analyst Downgrade
LIVN LivaNova	3.4078 of 5 stars	$77.21 +0.8%	$84.13 +9.0%	+50.7%	$4.22B	$1.39B	22.84	3,300	News Coverage Analyst Forecast
PLSE Pulse Biosciences	1.6226 of 5 stars	$52.32 +1.3%	$50.20 -4.1%	+205.7%	$3.66B	$350K	N/A	116	News Coverage Analyst Forecast
IRTC iRhythm Technologies	3.65 of 5 stars	$112.60 +2.0%	$179.93 +59.8%	-39.4%	$3.64B	$747.14M	N/A	2,400	News Coverage Analyst Forecast
ATRC AtriCure	2.647 of 5 stars	$58.41 +0.1%	$53.30 -8.7%	+54.3%	$2.97B	$534.53M	278.16	1,350	Positive News Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ENOV) was last updated on 10/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Enovis (ENOV) Competitors

ENOV vs. LIVN, PLSE, IRTC, ATRC, and TMDX

How does Enovis compare to LivaNova?

Summary

How does Enovis compare to Pulse Biosciences?

Summary

How does Enovis compare to iRhythm Technologies?

Summary

How does Enovis compare to AtriCure?

Summary

How does Enovis compare to TransMedics Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENOV vs. The Competition

Enovis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Enovis (ENOV) Competitors

ENOV vs. LIVN, PLSE, IRTC, ATRC, and TMDX

How does Enovis compare to LivaNova?

Does the media favor ENOV or LIVN?

Which has more volatility and risk, ENOV or LIVN?

Do insiders and institutionals hold more shares of ENOV or LIVN?

Do analysts rate ENOV or LIVN?

Which has stronger earnings and valuation, ENOV or LIVN?

Is ENOV or LIVN more profitable?

Summary

How does Enovis compare to Pulse Biosciences?

Does the media refer more to ENOV or PLSE?

Do institutionals and insiders believe in ENOV or PLSE?

Do analysts rate ENOV or PLSE?

Is ENOV or PLSE more profitable?

Which has stronger valuation & earnings, ENOV or PLSE?

Which has more volatility & risk, ENOV or PLSE?

Summary

How does Enovis compare to iRhythm Technologies?

Which has more volatility and risk, IRTC or ENOV?

Do analysts rate IRTC or ENOV?

Does the media favor IRTC or ENOV?

Which has preferable earnings and valuation, IRTC or ENOV?

Do institutionals & insiders hold more shares of IRTC or ENOV?

Is IRTC or ENOV more profitable?

Summary

How does Enovis compare to AtriCure?

Does the media prefer ENOV or ATRC?

Which has more risk & volatility, ENOV or ATRC?

Do insiders & institutionals believe in ENOV or ATRC?

Which has higher earnings & valuation, ENOV or ATRC?

Is ENOV or ATRC more profitable?

Do analysts rate ENOV or ATRC?

Summary

How does Enovis compare to TransMedics Group?

Do insiders and institutionals have more ownership in TMDX or ENOV?

Is TMDX or ENOV more profitable?

Do analysts recommend TMDX or ENOV?

Which has more risk and volatility, TMDX or ENOV?

Which has higher valuation and earnings, TMDX or ENOV?

Does the media refer more to TMDX or ENOV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENOV vs. The Competition

Enovis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools